Union College

RGT Wealth Advisors Announces Heather Pesikoff

Retrieved on: 
Tuesday, September 14, 2021
PricewaterhouseCoopers, Chamberlain Hrdlicka, RGT, University of Birmingham Financial Forum, BBVA USA, View, Union College, BBVA, Income tax, Multimedia, Political science, Phi Beta Kappa, National, Northeastern University School of Law, Head, Compliance, Organization, National Charity League, University School, Leadership, Management

HOUSTON, Sept. 14, 2021 /PRNewswire/ -- RGT Wealth Advisors ("RGT") is pleased to announce that Heather Pesikoff has joined the firm as a Managing Director, Chief Operating Officer and Chief Compliance Officer.

Key Points: 
  • HOUSTON, Sept. 14, 2021 /PRNewswire/ -- RGT Wealth Advisors ("RGT") is pleased to announce that Heather Pesikoff has joined the firm as a Managing Director, Chief Operating Officer and Chief Compliance Officer.
  • Prior to RGT, Heather served as Head of Specialized Trust Services at BBVA USA.
  • Preceding that, she served as Of Counsel at Chamberlain Hrdlicka, Managing Director at National Advisors Trust Company and Manager at PricewaterhouseCoopers.
  • Since 1985, RGT and its employees have dedicated themselves to serving as the advisors for individuals and families who desire a customized approach to their investment management and financial planning needs.

Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

Retrieved on: 
Monday, August 23, 2021
PD, Company, UnitedHealth Group, Richard Barker (life sciences and healthcare leader), Pramipexole, Group, Therapy, Brooklyn Law School, Parkinson, Acquisition, Union College, GLOBE, International, Schering-Plough, Walgreens Boots Alliance, Board of directors, Parkinson's disease, Merck & Co., Merck, Esperies, Commerce, Marketing, Alliance, Alliance Boots, Development, Gesellschaft mit beschränkter Haftung, List of life sciences, Board, Safety, Risk, Esperion Therapeutics, Patient, CEO, FDA, Pharmacy, Schering, Pharma, Technology, Pharmaceutical industry, Management

I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.

Key Points: 
  • I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • Mr. Berkowitz commented, "I am impressed by Pharma Two Bs progress to date and honored to be appointed as Chairman.
  • I look forward to working closely with Sheila and the rest of the Board and contributing to the company's future success."
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.

Triterras Bolsters Structured Finance Team with Key Appointments

Retrieved on: 
Wednesday, August 18, 2021
BA, Chambers, Private Securities Litigation Reform Act, NEPC, University, Associate, New Senior Investment Group, Growth, Binghamton University, U.S. Securities and Exchange Commission, Acquisition, Benjamin N. Cardozo School of Law, Union College, GLOBE, Xiamen, SEC, Science and technology in Asia, International development, Nasdaq, Digital technology, Solution, JD, Organization, ECAPS, MBA, Pennsylvania Public School Employees' Retirement System, Risk management, Head, COO, The Carlyle Group, Investment, Advisory board, Citigroup, Partnership, Goldman Sachs, HSBC Bank, Chartered Alternative Investment Analyst, CAIA, Fusion Global Business Solutions, Letter, Security (finance), Bank, Management, Sales

He will work closely with Triterras clientsinstitutional investors, including investment managers and asset owners in structuring deals and deploying capital to trade finance.

Key Points: 
  • He will work closely with Triterras clientsinstitutional investors, including investment managers and asset owners in structuring deals and deploying capital to trade finance.
  • With more than two decades of experience in asset management, Barbarinos knowledge and expertise will contribute to Triterras growth as a technology-enabled finance business.
  • He has deep experience in designing innovative structured finance transactions, as well as in alternative investment strategies, business development, and fintech.
  • In May, Triterras acquired Invoice Bazaar , a Dubai-based supply chain finance platform and hired a new Chief Technology Officer.

Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

Retrieved on: 
Thursday, August 12, 2021
Alliance Boots, Walgreens Boots Alliance, Gesellschaft mit beschränkter Haftung, Merck & Co., Board of directors, UnitedHealth Group, Schering-Plough, Pramipexole, GLOBE, List of life sciences, Pharma, FDA, Alliance, Therapy, Safety, CEO, Esperion Therapeutics, Marketing, Parkinson's disease, Schering, Acquisition, Union College, Development, Parkinson, Technology, Company, Esperies, Risk, Merck, International, Brooklyn Law School, PD, Commerce, Board, Group, Pharmacy, Richard Barker (life sciences and healthcare leader), Patient, Pharmaceutical industry, Management

REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.

Key Points: 
  • REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.
  • I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • Mr. Berkowitz commented, "I am impressed by Pharma Two Bs progress to date and honored to be appointed as Chairman.
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.